News & Videos - UNICYCIVE THERAPEUTICS INC.

EQS-News: Unicycive Therapeautics, Inc. Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive 08.12.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount to providers of dialysis...

EQS-News: Unicycive Therapeautics, Inc. Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden 08.11.2022 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 [email protected] Company Website https://unicycive.com/ News Source: News Direct 08.11.2022 CET/CEST Dissemination of a Corporate News,...

EQS-News: Unicycive Therapeautics, Inc. Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells 12.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? In addition to powering healthy cells, mitochondria are also important players in...

EQS-News: Unicycive Therapeautics, Inc. How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication 23.09.2022 / 15:12 CET/CEST The issuer is solely responsible for the content of this announcement. Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these,...

NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Unicycive Therapeutics. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc. Mark Roberts, Senior Editor at TradersNewsSource.com recently conducted the Interview...